Skip to search.
 TSX Up 0.40% TSX Ventures Down 1.68%

Incyte Corporation (INCY)

-NasdaqGS
84.53 Up 2.75(3.36%) 4:00PM EDT
|After Hours : 84.53 0.00 (0.00%) 4:28PM EDT - Nasdaq Real Time Price
Prev Close:81.78
Open:81.69
Bid:77.00 x 200
Ask:89.50 x 300
1y Target Est:91.57
Beta:0.5598
Earnings Date:Aug 2 - Aug 8 (Est.)
Day's Range:80.95 - 85.68
52wk Range:55.00 - 133.62
Volume:1,210,382
Avg Vol (3m):1,409,980
Market Cap:15.86B
P/E (ttm):340.85
EPS (ttm):0.25
Div & Yield:N/A (N/A)
Quotes delayed, except where indicated otherwise. Currency in USD.

Comparison

Symbol% ChgMkt Cap
INCYUp 3.36%15.86B
CELGUp 0.61%82.44B
AMGNUp 0.77%117.75B

Key Statistics

Forward P/E (1 yr):65.53
P/S (ttm):17.88
Ex-Dividend Date:N/A

Analysts

Annual EPS Est (Dec-16) :-0.01
Quarterly EPS Est (Jun-16) :-0.01
Mean Recommendation*:1.6
PEG Ratio (5 yr expected):-211.32

* (Strong Buy) 1.0 - 5.0 (Sell)

Analyst Opinion | Estimates

Business Summary

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. View More
Your browser doesn't support canvas
SETTINGS
Scrolling
Speed
Display
Price
Submit Feedback